Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders

A personalized medicine approach seems to be particularly applicable to psychiatry. Indeed, considering mental illness as deregulation, unique to each patient, of molecular pathways, governing the development and functioning of the brain, seems to be the most justified way to understand and treat di...

Full description

Saved in:
Bibliographic Details
Published inHeliyon Vol. 6; no. 5; p. e03990
Main Authors Levchenko, Anastasia, Nurgaliev, Timur, Kanapin, Alexander, Samsonova, Anastasia, Gainetdinov, Raul R.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.05.2020
Elsevier
Subjects
Bioinformatics
Biomarker
Evidence-based medicine
Genetics
Human brain
Machine learning
Mathematical biosciences
Molecular biology
Neuroscience
Pathophysiology
Pharmaceutical science
Pharmacotherapy
Psychiatry
RDoC
Schizophrenia
RDoC
Biomarker
Pathophysiology
Pharmacotherapy
Schizophrenia
Evidence-based medicine
Pharmaceutical science
Mathematical biosciences
Neuroscience
Machine learning
Human brain
Genetics
Molecular biology
Bioinformatics
Psychiatry
Online AccessGet full text

Cover

More Information
Summary:A personalized medicine approach seems to be particularly applicable to psychiatry. Indeed, considering mental illness as deregulation, unique to each patient, of molecular pathways, governing the development and functioning of the brain, seems to be the most justified way to understand and treat disorders of this medical category. In order to extract correct information about the implicated molecular pathways, data can be drawn from sampling phenotypic and genetic biomarkers and then analyzed by a machine learning algorithm. This review describes current difficulties in the field of personalized psychiatry and gives several examples of possibly actionable biomarkers of psychotic and other psychiatric disorders, including several examples of genetic studies relevant to personalized psychiatry. Most of these biomarkers are not yet ready to be introduced in clinical practice. In a next step, a perspective on the path personalized psychiatry may take in the future is given, paying particular attention to machine learning algorithms that can be used with the goal of handling multidimensional datasets. Neuroscience; Bioinformatics; Genetics; Pharmaceutical Science; Molecular Biology; Pathophysiology; Mathematical Biosciences; Psychiatry; Evidence-Based Medicine; Biomarker; human brain; Machine Learning; Pharmacotherapy; RDoC; schizophrenia
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2405-8440
2405-8440
DOI:10.1016/j.heliyon.2020.e03990